As far as we know, N-[2-(substituted-phenyl)ethyl]-4-quinazolinamines have been reported as acetyl- and butyrylcholinesterase inhibitors (AChE IC50 = 6.2 μM; BuChE IC50 = 14.1 μM) for the treatment of Parkinson disease and inhibitors of NFκB [65,66]. This evidence concerns the gene NFKB1 and Parkinson disease.